Similarly, other molecularly targeted therapies such as lenvatinib45 and cabozantinib46 exert their pleiotropic antitumour effects by acting on lymphoid and myeloid constituents of the tumour microenvironment both alone and in synergy with concurrent PD-1 pathway inhibition. This evidence concerns the gene PDCD1 and neoplasm.